Breast-cancer risk following long-term oestrogen-and oestrogen- progestin-replacement therapy

International Journal of Cancer

Volumn 81, Issue 3, 1999, Pages 339-344

  Magnusson, Cecilia ^a   Baron, John A ^a,b   Correia, Nestor ^a   Bergström, Reinhold ^a,c   Adami, Hans Olov ^a,d   Persson, Ingemar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d HARVARD CENTER FOR CANCER PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RISK; CASE CONTROL STUDY; DRUG USE; EPIDEMIOLOGICAL DATA; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 0032963863     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(19990505)81:3<339::aid-ijc5>3.0.co;2-6     Document Type: Article

References (18)

1. AMES, B.N. and GOLD, L.S., Too many rodent carcinogens: mitogenesis increases mutagenesis. Science, 249, 970-971 (1990).
2. BERGKVIST, L., ADAMI, H.O., PERSSON, I., BERGSTRÖM, R. and KRUSEMO, U.B., Prognosis after breast-cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Amer. J. Epidemiol., 130, 221-228 (1989).
3. BRESLOW, N.E. and DAY, N.E., Statistical methods in cancer research. Volume I. - The analysis of case-control studies. IARC Scientific Publication No. 32, pp. 5-338 (1980).
4. BRINTON, L.A., HOOVER, R. and FRAUMENI, J.F.J., Menopausal oestrogens and breast cancer risk: an expanded case-control study. Brit. J. Cancer, 54, 825-832 (1986).
5. CGHFBC (COLLABORATIVE GROUP ON HORMONAL FACTORS IN BREAST CANCER), Breast cancer and hormone replacement therapy, collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet, 350, 1047-1059 (1997).
6. COLDITZ, G.A., Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. nat. Cancer Inst., 90, 814-823 (1998).
7. COLDITZ, G.A., HANKINSON, S.E., HUNTER, D.J., WILLETT, W.C., MANSON, J.E., STAMPFER, M.J., HENNEKENS, C., ROSNER, B. and SPEIZER, F.E., The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. NewEngl. J. Med., 332, 1589-1593 (1995).
8. COMPEL, A., MALET, C., SPRITZER, P., LALARDRIE, J.P., KUTENN, F. and MAUVAIS-JARVIS, P., Progestin effect on cell proliferation and 17-B-hydroxysteroid dehydrogenase activity in normal breast cells in culture. J. clin. Endocrinol. Metab., 63, 1174-1180 (1986).
9. HARRIS, R.E., NAMBOODIRI, K.K. and WYNDER, E.L., Breast cancer risk: effects of estrogen replacement therapy and body mass. J. nat Cancer Inst., 84, 1575-1582 (1992).
10. HENDERSON, B.E., PAGANINI-HILL, A. and ROSS, R.K., Decreased mortality in users of estrogen replacement therapy. Arch. intern. Med., 151, 75-78 (1991).
11. HUNT, K., VESSEY, M., MCPHERSON, K. and COLEMAN. M., Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Brit. J. Obstet. Gynaecol., 94, 620-635 (1987).
12. KAAKS, R., Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Control. 7, 605-625 (1996).
13. MAGNUSSON, C., HOLMBERG, L., NORDÉN, T., LINDGREN, A. and PERSSON, I., Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res. Treat., 38, 325-334 (1996).
14. PERSSON, I., BERGKVIST, L. and ADAMI, H.O., Reliability of women's histories of climacteric oestrogen treatment assessed by prescription forms. Int. J. Epidemiol., 16, 222-228 (1987).
15. PERSSON, I., THURFJELL, E. and HOLMBERG, L., Effect of estrogen-progestin replacement regimens on mammographic breast parenchymal density. J. clin. Oncol., 15, 3201-3207 (1997).
16. POTTEN, C.S., WATSON, R.J., WILLIAMS, G.T., TICKLE, S., ROBERTS, S.A., HARRIS, M. and HOWELL, A., The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Brit. J. Cancer, 58, 163-170 (1988).
17. SCHAIRER, C., BYRNE, C., KEYL, P.M., BRINTON, L.A., STURGEON, S.R. and HOOVER, R.N., Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control, 5, 491-500 (1994).
18. YUEN, J., PERSSON, I., BERGKVIST, L., HOOVER, R., SCHAIRER, C. and ADAMI, H.O., Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for "healthy drug-user" effect. Cancer Causes Control. 4, 369-374 (1993).